SciSparc (NASDAQ: SPRC) to acquire TSXV company for $11.6 million

SciSparc Ltd. (NASDAQ: SPRC) entered into a definitive agreement on October 9, 2025, to acquire a controlling interest in Miza III Ventures Inc. (MIZA.P), a publicly traded company on the TSX Venture Exchange in Canada, according to a company statement.

Under the agreement, SciSparc will transfer its clinical-stage pharmaceutical portfolio and approximately 51% equity stake in SciSparc Nutraceuticals Inc. to Miza. The transferred assets are valued at approximately $11.6 million, while Miza’s total enterprise value is approximately $3.3 million.

SciSparc will receive 63.3 million common shares of Miza and up to 48 million contingent rights based on predetermined milestones. Following the transaction’s completion, SciSparc expects to hold between 75% and 84% of Miza. The acquired company plans to change its name to NeuroThera Labs Inc.

The TSX Venture Exchange has conditionally approved the transaction. Miza filed a statement regarding the proposed transaction on October 9, 2025, on its SEDAR+ profile.

Upon closing, SciSparc intends to provide up to CAD 1 million in capital to Miza through an unsecured convertible note with a 7% annual interest rate and two-year maturity. The note will be convertible into common shares at CAD 0.25 per share, up to a maximum of 4 million shares.

Miza will also issue 4 million common share purchase warrants to SciSparc at closing, exercisable at CAD 0.25 per share for five years.